Physician profile
Yan Lupyan
NPI 1841220829
$9,110.75
in general payments reported to CMS, 2019-2025
33 companies · $1,867 in 2025
The $1,867 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $985 · 2021: $1,540 · 2022: $1,694 · 2023: $1,065 · 2024: $1,172 · 2025: $1,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,066 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,065.60 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,552.72 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $826.49 | 2020-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Pfizer INC. | $754.40 | 2019-2025 | |
| Amgen INC. | $546.30 | 2019-2023 | Aimovig |
| Amneal Pharmaceuticals LLC | $459.91 | 2019-2025 | Crexont, Ongentys, Rytary |
| Azurity Pharmaceuticals, INC. | $432.59 | 2023-2025 | Horizant, Horizant |
| Horizon Therapeutics Plc | $425.08 | 2019-2022 | |
| Axsome Therapeutics, INC. | $378.20 | 2025 | Auvelity, Symbravo |
| Allergan, INC. | $354.00 | 2020-2022 | |
| Lilly USA, LLC | $349.60 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Biohaven Pharmaceutical Holding Company Ltd. | $348.95 | 2022 | |
| Eisai INC. | $329.50 | 2024-2025 | |
| Arbor Pharmaceuticals, INC. | $319.60 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $297.68 | 2019-2025 | Ztlido |
| Neurocrine Biosciences, INC. | $292.89 | 2019-2025 | Ingrezza, Ongentys |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $250.35 | 2020-2021 | |
| Acorda Therapeutics, INC | $176.17 | 2019 | |
| Kyowa Kirin, INC. | $135.72 | 2019-2023 | Nourianz |
| Biogen, INC. | $113.74 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $103.64 | 2019-2020 | |
| Argenx US, INC. | $92.86 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Almatica Pharma LLC | $84.59 | 2021 | |
| Sk Life Science, INC. | $84.38 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $65.55 | 2022 | |
| Ossdsign USA Incorporated | $65.06 | 2024 | |
| Assertio Therapeutics, INC. | $62.39 | 2019 | |
| Ucb, INC. | $42.66 | 2019 | |
| Impel Pharmaceuticals LLC | $39.46 | 2025 | Trudhesa |
| Lundbeck LLC | $38.54 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $22.24 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $22.18 | 2024 | |
| Impel Pharmaceuticals INC. | $21.88 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Lupyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.